Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Sezary Syndrome 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Melanoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 4Immunoblastic Lymphadenopathy 4Hodgkin Disease 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Intraocular Lymphoma 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × tanespimycin × Dermatologic × Clear all
NCT00104897 2013-06-26

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Dermatologic

Melanoma

NCT00004065 2013-06-24

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Blast Crisis, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Leukemia, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Esthesioneuroblastoma, Olfactory, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00087386 2013-04-10

Tanespimycin in Treating Patients With Stage III-IV Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
50 enrolled
Dermatologic

Melanoma

NCT00627419 2012-12-10

A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
1 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡